Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00828477

Enrollment

Registered

2009-01-26

Start date

2009-01-31

Completion date

2009-06-30

Last updated

2009-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular Pressure

Brief summary

The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

Detailed description

Open label, single armed, cross over controlled study to evaluate comfort and IOP (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes) scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.

Interventions

DRUGXibrom

Xibrom: two times a day for seven days in the first eye.

DRUGNevanac

Nevanac: three times a day for seven days in the second eye.

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* \> 18 years old, either gender or any race. * Diagnosis of open-angle glaucoma or ocular hypertension requiring laser trabeculoplasty. * Completion of written and informed consent/authorization prior to any study related procedures. * Able to follow study protocol and likely to complete study schedule.

Exclusion criteria

* Known sensitivity to NSAIDs. * History of neovascular or ocular inflammatory disease. * Current use of topical or systemic anti-inflammatory medications. * Females of childbearing potential.

Design outcomes

Primary

Measure	Time frame
Tolerability of study medication	28 days

Secondary

Measure	Time frame
Intraocular pressure changes	28 days
Visual Acuity	28 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026